Fertility & IVF

Care Fertility is one of the United Kingdom's largest independent providers of fertility treatment , operating a network of specialist clinics across England and Scotland. Founded in 1997, the group has grown into a leading name in reproductive medicine, offering the full spectrum of assisted conception services to patients and clinical partners alike. The clinic network covers treatments including IVF, ICSI, egg freezing, donor egg and donor sperm programmes, preimplantation genetic testing (PGT), and fertility preservation for patients facing medical circumstances such as cancer treatment. Care Fertility has invested substantially in its embryology laboratories and scientific infrastructure, and the group has been associated with research into embryo selection and time-lapse imaging technology. Care Fertility clinics hold licences from the Human Fertilisation and Embryology Authority (HFEA), the UK's statutory regulator for fertility treatment and embryo research, and the group publishes success rate data in line with HFEA reporting requirements. This transparency is central to how the network positions itself within the competitive UK fertility sector. The group serves both self-funding patients and those accessing NHS-funded cycles through clinical commissioning arrangements. Its clinics are located in cities including Nottingham, Manchester, Sheffield, Leeds, Birmingham, and London, giving the network broad geographic coverage across the country. Further information is available at carefertility.com.

Founded in 1963 by Bill Cook from a spare bedroom in Bloomington, Indiana, Cook Medical has grown into one of the world's largest family-owned medical device companies, a distinction that continues to shape its culture and long-term decision-making. Operating independently without the pressure of quarterly earnings reports, the company has remained focused on serving clinicians and patients across a broad portfolio of minimally invasive medical technologies. Minimally Invasive Devices Across Core Specialisms Cook Medical designs, manufactures, and distributes devices used in interventional radiology , endoscopy, urology, vascular surgery, and critical care. Its product catalogue spans thousands of items, including drainage catheters, stents, guidewires, biopsy tools, and endoscopic accessories. The company is particularly well regarded within interventional medicine for the depth of its vascular and biliary ranges, which are used in hospitals and procedural suites worldwide. Global Manufacturing and Distribution Headquartered in Bloomington, Indiana, Cook Medical maintains manufacturing facilities and offices across North America, Europe, Asia Pacific, and beyond, supplying products to more than 135 countries. The company employs tens of thousands of people globally and operates several dedicated business divisions, including Cook Biotech, which focuses on regenerative medicine technologies derived from naturally occurring tissue matrices, and Cook Regentec, which works on cell therapy platforms. Cook Medical has a long-standing reputation for close collaboration with physicians in device development. Many of its products originated from direct partnerships with clinicians who identified unmet procedural needs, a model the company has maintained throughout its history. This approach has led to iterative refinements across its endoscopy and urology portfolios in particular, where the breadth of available configurations allows for high procedural specificity. The company also maintains a strong commitment to training and education, providing simulation resources and hands-on programmes to support adoption of its technologies in clinical settings. Further information is available at cookmedical.com.

CooperSurgical has built one of the most comprehensive portfolios in women's health and fertility medicine, spanning devices, diagnostics, and assisted reproductive technology (ART) consumables used by clinicians across the globe. A subsidiary of The Cooper Companies (NYSE: COO), CooperSurgical operates as the dedicated women's health division of a publicly traded corporation headquartered in San Ramon, California. The business focuses on two broad segments: fertility, covering the products and services that support IVF laboratories and ART procedures, and office and surgical, covering gynaecological instruments, uterine health devices, and contraception. The fertility segment is particularly notable. CooperSurgical is widely recognised as a leading supplier to IVF clinics worldwide, offering ART consumables and media used throughout the embryology workflow, from oocyte handling through to embryo culture and transfer. This includes products from acquired brands such as Wallace, Origio, and The LifeGlobal Group, giving the company a broad reach across fertility laboratories in Europe, North America, Asia-Pacific, and beyond. On the surgical and office side, the company supplies instruments and devices for endometrial assessment, minimally invasive gynaecological procedures , and intrauterine contraception, including the well-known PARAGARD copper IUD, which it markets in the United States. CooperSurgical has grown substantially through acquisition, absorbing multiple specialist fertility and gynaecology businesses over the years. It serves healthcare providers ranging from large hospital systems to independent fertility clinics, positioning itself as a single-source partner for women's health product needs. Further information is available at coopersurgical.com.

Ferring Pharmaceuticals is the company behind desmopressin, the world's most widely prescribed treatment for bedwetting in children, and has built its entire identity around reproductive medicine and maternal health, areas where most large pharmaceutical companies remain peripheral players. Founded in 1950 by Frederik Pauling in Malmö, Sweden, Ferring has grown into a privately held, research-driven biopharmaceutical company operating in more than 100 countries across six continents. Reproductive Medicine & Women's Health Ferring holds a leading global position in reproductive medicine , supplying the gonadotropins and other hormone therapies that fertility clinics rely on at scale. Its Fertility portfolio includes products used in controlled ovarian stimulation protocols for in vitro fertilisation, making Ferring one of the few pharmaceutical companies for which assisted reproduction constitutes a primary, not peripheral, business line. The company has also invested heavily in maternal health, developing treatments to reduce the risk of preterm birth. Urology & Gastroenterology Beyond reproductive health, Ferring carries significant franchises in urology and gastroenterology. Its peptide-derived therapies span nocturia, enuresis and prostate cancer, reflecting a longstanding expertise in peptide science that dates to the company's earliest research. In gastroenterology, Ferring has pursued microbiome-based therapeutics, and in 2023 received FDA approval for Rebyota, the first faecal microbiota product approved for preventing recurrent Clostridioides difficile infection, a milestone that marks Ferring's entry into the emerging field of microbiome medicine . Headquartered in Saint-Prex, Switzerland, with major research operations in Copenhagen and commercial presence across North America, Europe and Asia-Pacific, Ferring remains family-owned and privately held, which affords it a longer investment horizon than many listed peers. The company consistently channels a substantial proportion of revenues back into research and development, particularly in peptide synthesis, reproductive endocrinology and next-generation microbiome therapies. Its scale, independence and therapeutic focus make it a distinctive reference point within the global specialty pharmaceuticals landscape. Further information is available at ferring.com.

Genea Biomedx is a specialist developer of equipment, software, and consumables purpose-built for the assisted reproductive technology (ART) laboratory. Originating from the scientific foundations of Genea, one of Australia's leading fertility networks, the company has translated decades of clinical IVF experience into a portfolio of products used by embryologists and fertility clinics across the globe. The company is perhaps best known for the Geri time-lapse incubator , a benchtop IVF incubator that allows continuous, undisturbed monitoring of developing embryos through integrated microscopy and imaging. This approach to time-lapse technology has made Genea Biomedx a recognised name in the embryology equipment sector, with the Geri platform adopted by fertility centres in dozens of countries. Beyond the incubator, the product range extends into embryo assessment software, culture media, cryopreservation solutions, and laboratory consumables, covering much of the workflow within a modern IVF laboratory. The company positions itself as an end-to-end partner for the ART lab rather than a single-product supplier. Headquartered in Sydney, Australia, Genea Biomedx operates commercially across Europe, the Americas, Asia-Pacific, and the Middle East, supported by a network of regional offices and distribution partners. Its dual heritage, part commercial medtech business and part spin-out from an active fertility clinic group, informs a product development philosophy grounded in day-to-day embryology practice. Further information is available at geneabiomedx.com.

Hamilton Thorne has built its reputation as the leading supplier of precision instruments and consumables for the assisted reproductive technology (ART) sector, serving IVF clinics, fertility research laboratories, and pharmaceutical and biotechnology companies worldwide. Founded in 1991 and headquartered in Beverly, Massachusetts, the company develops and markets a portfolio of laser systems, imaging systems, and embryo assessment software designed to improve clinical outcomes in human and animal reproductive medicine. Its LYKOS laser platform and OOSIGHT imaging systems are among the most widely recognised tools in clinical IVF environments globally. Hamilton Thorne is publicly traded on the TSX Venture Exchange under the ticker HLT, giving it a capital markets profile uncommon among specialist ART equipment suppliers. The company has grown significantly through acquisition, adding complementary businesses in consumables, cryopreservation, and laboratory services to build a more complete offering for fertility clinics and research organisations. Its customer base spans fertility clinics, academic research centres, and pharmaceutical companies conducting reproductive toxicology studies. The company also serves the animal breeding and veterinary reproduction market, supplying sperm analysis instruments and related products used in equine, bovine, and companion animal fertility work. Further information is available at hamiltonthorne.com.

The world's largest network of assisted reproduction clinics, IVIRMA Global was formed in 2017 when two established fertility leaders, IVI (founded 1990 in Valencia, Spain) and RMA (founded 1999 in the United States), merged to create a single, vertically integrated group spanning Europe, North America and Latin America. Headquartered in Valencia, the group has since grown to more than 200 clinical offices across 15 countries, treating patients who travel from more than 180 countries each year. Clinical Services Across the Reproductive Medicine Spectrum IVIRMA Global's clinical portfolio covers the full range of reproductive medicine, including in vitro fertilisation (IVF), intrauterine insemination, egg freezing and fertility preservation , third-party reproduction (donor eggs, donor sperm and gestational carriers), reproductive surgery (laparoscopy, hysteroscopy and myomectomy), and pre-implantation genetic testing. Services are structured to serve heterosexual couples, same-sex couples and single individuals. The group performs more than 200,000 assisted reproduction treatments annually, with approximately 100 babies born every day as a direct result of its programmes. Research, Science and the IVIRMA Innovation Network Scientific output is central to the group's identity. IVIRMA Innovation, its dedicated research arm, operates a network of fertility research centres and supports clinical trials, making the group one of the most cited organisations in peer-reviewed reproductive medicine literature. The group employs more than 6,000 people globally, including over 450 physicians and embryologists and more than 500 scientists and researchers. Patient-facing technology includes the Artemis Patient Portal, which centralises treatment management and communication. Financial access programmes, including a CareShare IVF refund programme, reflect a broader commitment to widening access to treatment. In 2025, IVIRMA Global continued its international expansion, acquiring ART Fertility Clinics in the United Arab Emirates and Saudi Arabia, extending its footprint into the Gulf region. Executive Chairman Dr Antonio Pellicer, one of the original founders of IVI, remains the public face of the group's scientific leadership. Further information is available at ivirma.com.

Spun off from Merck & Co. in 2021, Organon is a global healthcare company built around a focused mission: improving the health of women throughout their lives. Headquartered in Jersey City, New Jersey, Organon trades on the New York Stock Exchange under the ticker OGN and operates across more than 140 countries. The company's portfolio spans three core segments: women's health, biosimilars, and an established brands portfolio comprising off-patent medicines across cardiovascular, respiratory, dermatology, and other therapeutic areas. In women's health, Organon carries a broad range of contraceptive and reproductive health products, including intrauterine devices, implants, and hormonal contraceptives, making it one of the few global pharmaceutical companies with women's health as its central commercial focus. Organon's biosimilars portfolio, inherited in part from Merck's oncology and immunology pipeline, includes launched biosimilar versions of major reference biologics, positioning the company as a meaningful participant in the growing global biosimilars market. This segment offers healthcare systems cost-effective access to complex medicines at scale. With a workforce spanning multiple continents and a particular commercial emphasis on growth markets, Organon has structured its business to address both mature and emerging healthcare environments. Its established brands segment provides stable revenue that supports ongoing investment in women's health innovation and biosimilar development. Further information is available at organon.com.

Pioneering the science of human fertility, Vitrolife is a Swedish medtech company whose products are used in IVF clinics across more than 110 countries. Founded in 1994 and headquartered in Gothenburg, Sweden, the group has grown into one of the most recognised names in assisted reproductive technology, supplying the consumables, media and equipment that laboratories depend on throughout the IVF process. The company's portfolio centres on IVF culture media , time-lapse incubation systems, and associated laboratory consumables. Its time-lapse technology, which allows embryologists to monitor embryo development continuously without disturbing the culture environment, has become widely adopted in fertility clinics worldwide. Vitrolife is listed on Nasdaq Stockholm, reflecting its standing as a significant publicly traded entity in the European medtech sector. A major expansion came through the acquisition of Igenomix in 2021, broadening Vitrolife's capabilities into reproductive genetics , including preimplantation genetic testing services used to assess embryo chromosomal status before transfer. This move extended the group's reach well beyond physical laboratory products and into genomic diagnostics for fertility treatment. Vitrolife operates its own manufacturing and research facilities, and its scientific teams publish regularly in peer-reviewed reproductive medicine literature. The company serves fertility specialists, reproductive biologists, and IVF laboratory directors, positioning itself as a full-cycle partner from fertilisation through embryo selection and transfer. Further information is available at vitrolife.com.